Cargando…

SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test

The SARS-CoV-2 neutralizing antibodies response is the best indicator of effective protection after infection and/or vaccination, but its evaluation requires tedious cell-based experiments using an infectious virus. We analyzed, in 105 patients with various histories of SARS-CoV-2 infection and/or v...

Descripción completa

Detalles Bibliográficos
Autores principales: Marot, Stephane, Bocar Fofana, Djeneba, Flandre, Philippe, Malet, Isabelle, Zafilaza, Karen, Leducq, Valentin, Vivien, Diane, Mrabet, Sarah, Poignon, Corentin, Calvez, Vincent, Morand-Joubert, Laurence, Marcelin, Anne-Geneviève, Gozlan, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782962/
https://www.ncbi.nlm.nih.gov/pubmed/36556429
http://dx.doi.org/10.3390/life12122064
_version_ 1784857464274944000
author Marot, Stephane
Bocar Fofana, Djeneba
Flandre, Philippe
Malet, Isabelle
Zafilaza, Karen
Leducq, Valentin
Vivien, Diane
Mrabet, Sarah
Poignon, Corentin
Calvez, Vincent
Morand-Joubert, Laurence
Marcelin, Anne-Geneviève
Gozlan, Joel
author_facet Marot, Stephane
Bocar Fofana, Djeneba
Flandre, Philippe
Malet, Isabelle
Zafilaza, Karen
Leducq, Valentin
Vivien, Diane
Mrabet, Sarah
Poignon, Corentin
Calvez, Vincent
Morand-Joubert, Laurence
Marcelin, Anne-Geneviève
Gozlan, Joel
author_sort Marot, Stephane
collection PubMed
description The SARS-CoV-2 neutralizing antibodies response is the best indicator of effective protection after infection and/or vaccination, but its evaluation requires tedious cell-based experiments using an infectious virus. We analyzed, in 105 patients with various histories of SARS-CoV-2 infection and/or vaccination, the neutralizing response using a virus neutralization test (VNT) against B.1, Alpha, Beta and Omicron variants, and compared the results with two surrogate assays based on antibody-mediated blockage of the ACE2-RBD interaction (Lateral Flow Boditech and ELISA Genscript). The strongest response was observed for recovered COVID-19 patients receiving one vaccine dose. Naïve patients receiving 2 doses of mRNA vaccine also demonstrate high neutralization titers against B.1, Alpha and Beta variants, but only 34.3% displayed a neutralization activity against the Omicron variant. On the other hand, non-infected patients with half vaccination schedules displayed a weak and inconstant activity against all isolates. Non-vaccinated COVID-19 patients kept a neutralizing activity against B.1 and Alpha up to 12 months after recovery but a decreased activity against Beta and Omicron. Both surrogate assays displayed a good correlation with the VNT. However, an adaptation of the cut-off positivity was necessary, especially for the most resistant Beta and Omicron variants. We validated two simple and reliable surrogate neutralization assays, which may favorably replace cell-based methods, allowing functional analysis on a larger scale.
format Online
Article
Text
id pubmed-9782962
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97829622022-12-24 SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test Marot, Stephane Bocar Fofana, Djeneba Flandre, Philippe Malet, Isabelle Zafilaza, Karen Leducq, Valentin Vivien, Diane Mrabet, Sarah Poignon, Corentin Calvez, Vincent Morand-Joubert, Laurence Marcelin, Anne-Geneviève Gozlan, Joel Life (Basel) Article The SARS-CoV-2 neutralizing antibodies response is the best indicator of effective protection after infection and/or vaccination, but its evaluation requires tedious cell-based experiments using an infectious virus. We analyzed, in 105 patients with various histories of SARS-CoV-2 infection and/or vaccination, the neutralizing response using a virus neutralization test (VNT) against B.1, Alpha, Beta and Omicron variants, and compared the results with two surrogate assays based on antibody-mediated blockage of the ACE2-RBD interaction (Lateral Flow Boditech and ELISA Genscript). The strongest response was observed for recovered COVID-19 patients receiving one vaccine dose. Naïve patients receiving 2 doses of mRNA vaccine also demonstrate high neutralization titers against B.1, Alpha and Beta variants, but only 34.3% displayed a neutralization activity against the Omicron variant. On the other hand, non-infected patients with half vaccination schedules displayed a weak and inconstant activity against all isolates. Non-vaccinated COVID-19 patients kept a neutralizing activity against B.1 and Alpha up to 12 months after recovery but a decreased activity against Beta and Omicron. Both surrogate assays displayed a good correlation with the VNT. However, an adaptation of the cut-off positivity was necessary, especially for the most resistant Beta and Omicron variants. We validated two simple and reliable surrogate neutralization assays, which may favorably replace cell-based methods, allowing functional analysis on a larger scale. MDPI 2022-12-09 /pmc/articles/PMC9782962/ /pubmed/36556429 http://dx.doi.org/10.3390/life12122064 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Marot, Stephane
Bocar Fofana, Djeneba
Flandre, Philippe
Malet, Isabelle
Zafilaza, Karen
Leducq, Valentin
Vivien, Diane
Mrabet, Sarah
Poignon, Corentin
Calvez, Vincent
Morand-Joubert, Laurence
Marcelin, Anne-Geneviève
Gozlan, Joel
SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test
title SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test
title_full SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test
title_fullStr SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test
title_full_unstemmed SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test
title_short SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test
title_sort sars-cov-2 neutralizing responses in various populations, at the time of sars-cov-2 variant virus emergence: evaluation of two surrogate neutralization assays in front of whole virus neutralization test
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782962/
https://www.ncbi.nlm.nih.gov/pubmed/36556429
http://dx.doi.org/10.3390/life12122064
work_keys_str_mv AT marotstephane sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest
AT bocarfofanadjeneba sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest
AT flandrephilippe sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest
AT maletisabelle sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest
AT zafilazakaren sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest
AT leducqvalentin sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest
AT viviendiane sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest
AT mrabetsarah sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest
AT poignoncorentin sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest
AT calvezvincent sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest
AT morandjoubertlaurence sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest
AT marcelinannegenevieve sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest
AT gozlanjoel sarscov2neutralizingresponsesinvariouspopulationsatthetimeofsarscov2variantvirusemergenceevaluationoftwosurrogateneutralizationassaysinfrontofwholevirusneutralizationtest